Epidermal growth factor (EGF) plays a key role in survival of neural and glial precursor cells. The +61A/G polymorphism of the EGF gene is located in the 5-untranslated region of EGF mRNA and may affect DNA folding or gene transcription, leading to the increase in EGF protein expression. The association between the +61G allele and glioma risk has been widely reported; however, in general the data from published studies with individually low statistical power were controversial and underpowered. We conducted a search in the PubMed database without a language limitation, covering all papers published by the end of October 2010. Overall, 6 case-control studies with 1453 glioma cases and 1947 controls were retrieved based on the search criteria for glioma susceptibility related to the +61A/G polymorphism. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the association. We found that EGF +61G allele is associated with the low glioma risk in Chinese population [G-allele vs. A-allele, OR = 0.93, 95%CI (0.89-0.97), P heterogeneity = 0.318, I 2 = 0.0], but with the high glioma risk in European population [G-allele vs. A-allele, OR = 1.14, 95%CI (1.04-1.24), P heterogeneity = 0.310, I 2 = 14.6]. In the stratified analysis by source of control, significant association was observed between hospital-based control and glioma risk [homozygote comparison, OR = 1.14, 95%CI (1.02-1.27), P heterogeneity = 0.179, I 2 = 71.8]. In conclusion, EGF +61G allele represents a risk factor for glioma in European population and conversely a protective factor in Chinese population.
Central nervous system tumors represent only 2% of all cancer deaths, and glioma is the most frequent central nervous system tumors (Jemal et al. 2009 ), which can be divided into astrocytoma, glioblastoma, ependymocytoma, oligodendroglioma, mixed glioma, pinealoma and papilloma choroideum. According to the WHO classification, glioma can be classified into four grades of malignancy (Louis et al. 2007) . Despite all advances in neurosurgery and adjuvant radiotherapy and chemotherapy, the median survival time of patients with malignant glioma remains only approximately 12 months, while less than 3% of glioblastoma patients survive for 5 years after diagnosis (Ohgaki and Kleihues 2005) . Previous studies (Chen et al. 2000; Wrensch et al. 2002) suggested that some factors such as workplace, dietary, and other personal and residential exposures might result in glioma, as well as the genetic factors such as single nucleotide polymorphisms (SNPs).
Numerous studies have investigated the risk of glioma associated with the +61A/G polymorphism of the epidermal growth factor (EGF) gene. EGF, located in chromosome 4q25-q27 (Normanno et al. 2006) , contains 24 exons and 23 introns and encodes a ligand for the EGF receptor (EGFR).
As an endocrine growth factor, EGF can activate DNA synthesis, cellular differentiation and proliferation, survival of neural and glial precursor cells and is implicated in the development of the nervous system via binding with EGFR (Xian et al. 2001) . EGF is overexpressed in malignant glioma, breast, pancreas and liver carcinoma, indicating its vital role in malignant cell transformation, tumor occurrence and development by promoting cell division (Xian et al. 2001; Zhu and Parada 2002; Jorissen et al. 2003) . In addition, several mechanisms such as autocrine/paracrine stimulation loops, EGFR gene amplification and activating mutations (e.g., EGF +61A/G and EGFR vIII) can alter the EGF/EGFR signaling pathway, which are associated with gliomagenesis, invasion and malignancy (Ekstrand et al. 1991; Salomon et al. 1995; Zhu and Parada 2002) .
A study (Shahbazi et al. 2002) first reported a functional EGF +61A/G SNP (rs4444903) that is located in the 5´-untranslated region of EGF mRNA. They demonstrated that the G allele had an increased EGF protein expression by affecting DNA folding or gene transcription in vitro and revealed that patients with malignant melanoma of skin had a significantly higher frequency of G allele compared with the general population. Besides melanomas, another study (Bhowmick et al. 2004) showed a relationship between this functional polymorphism and the risk in aggressiveness of glioblastoma. By studying 42 American patients, they found that the frequency of G allele and the frequency of GA or GG genotypes were significantly higher in glioblastoma patients than in healthy individuals. To date, with regard to glioma, a total of 6 studies have been reported from North America (Bhowmick et al. 2004 ), South America (Pinto et al. 2009 ), Europe (Costa et al. 2007; Vauleon et al. 2007 ) and China (Liu et al. 2009; Wang et al. 2010 ), but their results are conflicting.
Taking into consideration of the extensive role of EGF in glioma, hence, to derive a more precise estimation of the association of +61A/G polymorphism between EGF and glioma, we performed a meta-analysis of all eligible casecontrol studies.
Materials and Methods

Literature search
We conducted searches on the PubMed database (http://www. ncbi.nlm.nih.gov/), last search updated on July 20 2010, with the keywords 'EGF' or 'epidermal growth factor', 'polymorphism' and 'glioma', without any restriction on language or publication year. Using these terms, a total of 19 articles were retrieved, of which 6 articles coincide the inclusion criteria. We also screened reference of the retrieved articles and review articles by a hand search.
Inclusion criteria and exclusion criteria
Eligible studies had to meet the following criteria: (a) the study assessed the correlation between glioma and EGF +61A/G polymorphism cited above; (b) case-control studies; (c) control subjects matched with case patients for age and gender and (d) only full-text manuscripts were included. Major exclusion criteria were (a) no control population; (b) no available genotype frequency and (c) duplication of the previous publications.
Data extraction
Two of the authors reviewed results of each of the database searches to make sure that published papers are not missed. Data were collected on the first author's last name, year of publication, country of origin, ethnicity, total case/control number, subjects of genotype in cases and controls, source of control, Hardy-Weinberg equilibrium (HWE) of controls, frequency of G allele and genotyping methods.
Statistic analysis
Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to measure the strength of the association between EGF +61A/G polymorphism and glioma based on the genotype frequencies in cases and controls. Subgroup analysis stratified by ethnicity was performed first. Ethnicity was categorized as European, Chinese and Mixed. Source of control subgroup analysis was performed on two classifications: population-based and hospital-based.
The fixed effects model and the random effects model were used to calculate the pooled OR. The statistical significance of the summary OR was determined with the Z-test. Heterogeneity assumption was evaluated with a chi-square-based Q test among the studies. A P value of more than 0.05 for the Q-test indicated a lack of heterogeneity among the studies. In case significant heterogeneity was detected, the random effects model (DerSimonian-Laird method) was used (DerSimonian and Laird 1986), whereas, the fixed effects model (Mantel-Haenszel method) was chosen (Mantel and Haenszel 1959) . In order to better evaluate the extent of heterogeneity between studies, the I 2 test was also used. As a guide, I 2 values of < 25% may be considered 'low', value of ~50% may be considered 'moderate' and values of > 75% may be considered 'high' (Higgins et al. 2003) .
For EGF +61A/G, we investigated the association between genetic variants and glioma risk in allelic contrast (G-allele vs. A-allele), homozygote comparison (GG vs. AA), heterozygote comparison (GA vs. AA), dominant genetic model (GG+GA vs. AA) and recessive genetic model (GG vs. GA+AA). The funnel plot asymmetry was assessed with Egger's test. Publication bias was assessed with Egger's test, P < 0.05 was considered statistically significant (Egger et al. 1997 ). The departure of frequencies of EGF polymorphism from expectation under HWE was assessed by χ 2 test in controls using the Pearson chi-square test for goodness of fit, P < 0.05 was considered significant. All statistical tests for this meta-analysis were performed with STATA software (version 10.0; StataCorp LP, College Station, TX).
Genotyping methods
Genotyping for SNP of EGF gene was conducted using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) (Costa et al. 2007; Pinto et al. 2009; Liu et al. 2009 ), real-time PCR (Vauleon et al. 2007 ), quantitative reverse transcription-PCR (qRT-PCR) (Bhowmick et al. 2004 ) and PCR-ligation detection reaction (PCR-LDR) .
Results
Meta-analysis databases
We established a database according to the extracted information from each article. All essential information was listed in Table 1. Table 1 showed first author, publishing year, ethnicity, the numbers of cases and controls, HWE and frequency of G allele in the control, genotyping methods and source of control. Overall, 6 studies with 1453 glioma cases and 1947 controls were retrieved based on the search criteria for glioma susceptibility related to the EGF +61A/G polymorphism. The Brazillian population in one study (Pinto et al. 2009 ) really is one of the most heterogeneous populations in the world. The population should not be as pure European, but as the mixed population. So in our study, there are three European case-control studies, two Chinese case-control studies and one mixed case-control study. With the exception of one study (Vauleon et al. 2007) , the distribution of genotypes among the controls was in agreement with HWE. Table 2 shows the relationship between the EGF +61A/ G polymorphism and glioma risk. The heterogeneity of EGF +61A/G allelic contrast, homozygote comparison, heterozygote comparison, dominant genetic model or recessive genetic model was analyzed for 6 case-control studies. Random-effect models were used to analyze the OR for total population (G-allele vs. A-allele, GG vs. AA and GG vs. GA+AA), population-based control (G-allele vs. A-allele, GG vs. AA and GG vs. GA+AA) and mixed ethnicity (all genetic models). Moreover, fixed-effect models were used to analyze the OR for the rest.
Test of heterogeneity
Quantitative data synthesis Table 2 shows that the summary odds ratios of EGF +61A/G on the basis of 1453 glioma cases and 1947 controls, we did not observe an association between the EGF +61A/G polymorphism and glioma in total population. Given the ethnic differences in the allele frequency of this sequence variant, we evaluated the effect of EGF +61A/G polymorphism in Chinese, European and mixed population, respectively. Association of +61G allele with decreased glioma risk in Chinese population was observed under allelic contrast [OR = 0.93, Fig. 3] , however, association of +61G allele with increased glioma risk in European population was observed under allelic contrast [OR = 1.14, 95%CI (1.04-1.24), P = 0.003, I 2 = 14.6; Fig. 1 ], homozygote comparison [OR = 1.33, 95%CI (1.12-1.60), P = 0.002, I 2 = 0.0; Fig. 2 ] and recessive genetic model [OR = 138, 95%CI (1.12-1.71), P = 0.003, I 2 = 30.1; Fig. 3 ]. Summary odds ratios for +61A/G polymorphism stratified by source of control were evaluated, and we also observed an increased association in the homozygote comparison [OR = 1.14, 95%CI (1.02-1.27), P = 0.021, I 2 = 71.8] on the basis of hospital-based control.
Publication bias
The Begg's funnel plot and Egger's test were performed to access the publication bias of literatures. The shape of the funnel plots seemed asymmetrical in allele comparison for EGF +61A/G polymorphism, suggesting the presence of publication bias. Then, Egger's test was used to provide statistical evidence of funnel plot symmetry. However, an obvious evidence of publication bias was shown by the ethnicity (recessive genetic model, t = 3.91, P = 0.017; Table 3 ).
Discussion
Glioma carcinogenesis is a complex and still poorly understood process in which environmental and genetic factors cooperate with each other (Ohgaki and Kleihues 2005) . Recently, several studies have focused on the etiologic role of germ line genetic polymorphisms in glioma development and prognosis (Wrensch et al. 2005) . These studies included analysis of genes encoding proteins involved in DNA repair pathways (e.g., MGMT, XRCC7, and ERCC2), carcinogen metabolism (e.g., GST and CYP2D6) and growth pathway (EGF). The EGF/EGFRmediated pathway is one of the most critical pathways for glioma tumorigenesis (Feldkamp et al. 1997 ) and functional polymorphisms involving EGF or EGFR may affect glioma development.
EGF can activate multiple signaling pathways involved in cell proliferation, differentiation and tumorigenesis (Limaye et al. 2008) . Overexpression of EGF is also associated with growth and invasion of some malignant tumors via autocrine and paracrine pathways (Stoscheck and King 1986) . Some studies have reported conflicting findings on the association of EGF +61A/G polymorphism with the risk and prognosis of glioma. Bhowmick et al. (2004) first studied the role of this SNP in a subtype of glioma, suggesting that the +61G allele was strongly associated with risk (P < 0.001) and shorter overall survival (P = 0.036) of glioblastoma patients from North America; Costa et al. (2007) also found an association between the +61G allele and an increased risk, not only of glioblastoma (OR: 1.47), but also of oligodendroglioma (OR: 1.55) and whole glioma (OR: 1.32); however, Kaplan-Meier analysis did not show any statistically significant correlation between this polymorphism and the survival of glioblastoma (P = 0.365) or oligodendroglioma (P = 0.459). However, in a recently study, Wang et al. (2010) indicated that GA (P = 0.001) and AA (P = 0.005) genotypes or EGF +61A allele (P = 0.001) were associated with higher glioma risk in Chinese.
Previously, two independent studies Zhang et al. 2010) performed two meta-analysis of the association of EGF +61A/G polymorphism and glioma risk, they only contained three case-control studies; however, a largest sample case-control study ) and another eligible study (Pinto et al. 2009) were not included, which might make their conclusions questionable. To i n d i c a t e t h e r e l a t i o n s h i p b e t w e e n E G F + 6 1 A / G polymorphism and glioma risk, to the best of our knowledge, we performed a meta-analysis involving 1453 glioma cases and 1947 controls, three European case- control studies, two Chinese case-control studies and one mixed case-control study. The main message of this metaanalysis is that the association between EGF +61A/G polymorphism and glioma risk is modified by race. EGF +61G allele represents an increased risk factor for glioma in European population and a protective factor in Chinese population.
Given its important role in cellular proliferation, survival, migration and differentiation, a functional polymorphism in the EGF gene has been reported to be associated with the EGF gene expression or an increased risk of solid tumors, making them potential predictive markers for clinical outcomes (Bhowmick et al. 2004; Costa et al. 2007; Pinto et al. 2009 ). Therefore, a polymorphism in the 5´-untranslated region of the EGF gene may alter expression of EGF and subsequently influence susceptibility to glioma. As for +61A/G polymorphism of EGF, our result showed that EGF +61G allele could protect Chinese population against glioma; in contrast, EGF +61G allele could increase glioma risk in Europeans. Consider the different allele frequency between Chinese and European population, further studies are needed to explore the role of EGF +61A/G polymorphism in glioma development in different ethnicities.
In our study we also found an association between EGF +61A/G polymorphism and glioma risk in hospitalbased control. The distribution of genotypes in the controls by Vauleon et al. (2007) was not consistent with the HWE, when excluding it, significant heterogeneity did not change and the positive association still existed.
Some limitations of this meta-analysis should be mentioned. First of all, the number of published studies included in our meta-analysis was not sufficiently large for a comprehensive analysis, and one study (Bhowmick et al. 2004 ) with small sample size may not have enough statistical power to explore the real association. Second, publication bias might have occurred and our Egger's test results may have a substantial risk of being affected by such bias. Third, the interactions between gene-gene, geneenvironment and even different polymorphic loci of the same gene may modulate glioma risk. Fourth, our metaanalysis was based on unadjusted estimates, while a more precise analysis should be conducted if individual data were available, which would allow for the adjustment by other covariates including age, sex, family history, environmental factors, cancer stage and lifestyle. Fifth, the controls were not uniformly defined. If considering these factors, our meta-analysis should be interpreted with caution. In spite of these, our meta-analysis also had two advantages. First, substantial number of cases and controls were pooled from different studies, which significantly increased statistical power of the analysis. Second, the quality of case-control studies included in the current meta-analysis was satisfactory based on our selection criteria.
In summary, our meta-analysis provides the evidence that EGF +61G allele is associated with increased glioma risk in European population, but may decrease glioma risk in Chinese population and play a protective role in future therapy, which supported the hypothesis that this poly- The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI. morphism may be a low-penetrance susceptibility biomarker for glioma. Therefore, further well designed large studies, particularly referring to gene-gene and gene-environment interactions are warranted. These future studies should lead to better and comprehensive understanding of the association between the EGF +61A/G polymorphism and glioma risk.
